A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Diagnosis of Type 1 or 2 diabetes mellitus.

• Diagnosis of painful DPN for at least 12 months but less than 5 years in duration.

Exclusion Criteria:

• Neurologic Disorders unrelated to diabetic neuropathy that may confuse or confound the assessment of neuropathic pain.

• Presence of any severe pain associated with conditions other than DPN that may confuse or confound the assessment of neuropathic pain.